Patents by Inventor Marcin OKROJ

Marcin OKROJ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor B and C2 protein point mutants, a method for enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants
    Patent number: 11414468
    Abstract: The subject of this invention is point mutants of human proteins constituting the complement system's C3 and C5 convertases, where the mutation are as follows: For the factor B: —D279G, F286L, K323E, Y363A; D279G_F286L_K323E_Y363A—quadruple mutant; For the C2 protein: —C261A, Q.263G, Y347A, L348A; T442Q, double mutants C261A_Q263G and Y347A_Q263G, triple mutant Y347A_Q263G_T442Q The subject of this invention is the method of enhancing the activity of the anti-cancer antibodies, which includes the addition of mutants defined above. The subject of this invention is the pharmaceutical composition, which includes the therapeutically effective number of mutants defined above. The subject of this invention is the use of mutants defined above to enhance the cytotoxic activity of anti-cancer antibodies in therapy and in the treatment of neoplastic diseases.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 16, 2022
    Assignee: GDANSKI UNIWERSYTET MEDYCZNY
    Inventors: Marcin Okroj, Anna Felberg-Mietka, Aleksandra Urban
  • FACTOR B AND C2 PROTEIN POINT MUTANTS, A METHOD FOR ENHANCING THE ACTIVITY OF ANTI-CANCER ANTIBODIES, THE PHARMACEUTICAL COMPOSITION AND THE USE OF MUTANTS
    Publication number: 20210163553
    Abstract: The subject of this invention is point mutants of human proteins constituting the complement system's C3 and C5 convertases, where the mutation are as follows: For the factor B:—D279G, F286L, K323E, Y363A; D279G_F286L_K323E_Y363A-quadruple mutant; For the C2 protein:—C261A, Q.263G, Y347A, L348A; T442Q, double mutants C261A_Q263G and Y347A_Q263G, triple mutant Y347A_Q263G_T442Q The subject of this invention is the method of enhancing the activity of the anti-cancer antibodies, which includes the addition of mutants defined above. The subject of this invention is the pharmaceutical composition, which includes the therapeutically effective number of mutants defined above. The subject of this invention is the use of mutants defined above to enhance the cytotoxic activity of anti-cancer antibodies in therapy and in the treatment of neoplastic diseases.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 3, 2021
    Inventors: Marcin OKROJ, Anna FELBERG-MIETKA, Aleksandra URBAN